We use cookies.
By using the site, you agree to our Privacy Policy.

Laboratory of Theranostics in Urologic Oncology

Invited researcher Thierry Jean Paul Roger
Contract number
075-15-2019-1927
Time span of the project
2019-2021

As of 15.02.2021

39
Number of staff members
5
scientific publications
General information
Name of the project: Theranostics in urologic oncology

Strategy for Scientific and Technological Development Priority Level: в

Goals and objectives

Project objective:

  • Creation of a world-class laboratory conducting breakthrough biomedical research in the domain of therapy and diagnostics of urologic oncology with a focus on bladder cancer
  • Implementation of a research program that is on the frontier of theranostics of oncological diseases in urology and aimed at translation to clinical practice
The practical value of the study

It is known that according to the clinical picture, bladder cancer (BC) can be divided into three stages as the disease progresses: early stage, late stage and metastatic cancer. Early (superficial) bladder cancer (most common, 75–85% of diagnosed tumors) is most commonly referred to as non-muscle invasive bladder cancer (NMIBC). Advanced bladder cancer is called muscle invasive bladder cancer (MIBC) and covers tumors in stages T2a through T4b. The most advanced stage of BC, in which the tumor spreads to nearby or distant organs, is called metastatic bladder cancer. Despite the fact that more than 70% of patients are initially diagnosed with NMIBC, disease recurrence in most cases occurs first as NMIBC and subsequently as MIBC. In terms of treatment strategy, the two diagnoses of NMIBC and MIBC differ greatly, and stratification of bladder cancer based on molecular subtype can be a very effective approach for determining treatment regimen. In addition to the differentiation of molecular subtypes based on the analysis of gene expression profiles in bladder cancer tumors, the development and testing of non-invasive techniques for the isolation of circulating tumor cells from biological fluids of patients is of great importance. The developed technique for isolating prostate cancer (PC) cells from urine using a microfluidic chip has shown high efficiency and was tested for isolating PC cells from the semen of patients with non-metastatic PC at an early stage. The development of drug delivery systems capable of effective adhesion to the bladder mucosa and the analysis of the distribution of nanosized containers in in vitro and in vivo models of bladder cancer, as well as pharmacokinetic studies of targeted containers are also important points of current research.

Implementation of research results :

A high-performance microfluidic chip for enriching urine-derived bladder cancer cells has been developed and investigated.

The pharmaceutical product A83-01 was synthesized, as well as a new biomaterial with biodegradability at neutral acidity.

Colloidally stable in salt solutions polymer nanoparticles with a size of about 200 nm, loaded with a chemotherapeutic drug and a fluorescent dye, have been synthesized. The resulting polymer nanoparticles were successfully modified with a HER2-recognition protein while maintaining the stability of the nanoparticles.

Upon completion of the program, results will be obtained that will improve our understanding of the development, resistance and metastasis of bladder carcinoma, based on the analysis and interpretation of big data of the genome and transcriptome, based on the developments of a leading scientist in this field. Based on an understanding of the molecular characteristics of urological tumors, a new generation of theranostic agents will be developed that will allow diagnosing bladder cancer and prostate cancer at an early stage, providing new opportunities for precision diagnostics and personalized therapy, as well as monitoring cancer therapy for bladder cancer and prostate cancer.

Education and retraining of personnel:

At present, the programs of new training courses “Nanotechnology and Nanomedicine”, “Microfluidics in Biology and Medicine” are being created, and it is planned to publish textbooks on these topics.

Members of the research team took part in the conference VIII International conference with elements of a scientific school for young people "Functional nanomaterials and high-purity substances" (FNM 2020), Suzdal, October 5-9, 2020.

It is planned to defend three candidate dissertations and one doctoral dissertation.

The members of the research team were trained in refresher courses.

Infrastructure transformations:

Since 2019, the Laboratory "Theranostics in Urological Oncology" has been part of the Department of Biomedical Engineering of the Institute of Molecular Medicine of the Scientific and Technological Park of Biomedicine of the I.M. THEM. Sechenov, Ministry of Health of Russia (Sechenov University).

Collaborations:

Federal State Autonomous Educational Institution of Higher Education “National Research Nizhny Novgorod State University named after N.I. Lobachevsky "(Russia), Macquarie University (Australia), Institute of Bioorganic Chemistry named after academicians M. M. Shemyakin and Yu. A. Ovchinnikov RAS (Russia), Federal State Institution" Federal Research Center "Crystallography and Photonics" of the Russian Academy of Sciences "(Russia), Federal State Budgetary Institution of Science Institute of Theoretical and Experimental Biophysics of the Russian Academy of Sciences (Russia), Federal State Autonomous Educational Institution of Higher Education" National Research Technological University "MISIS" (Russia), Autonomous Non-Commercial Educational Organization of Higher Education "Skolkovo Institute science and technology "(Russia): joint research and publications.

Hide Show full
D. M. Polikarpov, D. H. Campbell, L. S. McRobb, J. Wu, M. E. Lund, Ya. Lu, S. M. Deyev, A. S. Davidson, B. J. Walsh, A. V. Zvyagin, and D. A. Gillatt
Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery, Cancers 12, 984 (2020). doi:10.3390/cancers12040984
A. S. Rzhevskiy, S. R. Bazaz, L. Ding, A. Kapitannikova, N. Sayyadi, D. Campbell, B. Walsh, D. Gillatt, M. E. Warkiani, and A. V. Zvyagin
Rapid and Label-Free Isolation of Tumour Cells from the Urine of Patients with Localised Prostate Cancer Using Inertial Microfluidics, Cancers 12 (1), 81 (2020). doi: 10.3390/cancers12010081
I. V. Krylov, R. A. Akasov, V. V. Rocheva, N. V. Sholina, D. A. Khochenkov, A. V. Nechaev, N. V. Melnikova, A. A. Dmitriev, A. V. Ivanov, A. N. Generalova, and E. V. Khaydukov
Local Overheating of Biotissue Labeled with Upconversion Nanoparticles Under Yb3+ Resonance Excitation, Front. Chem. 8, 295 (2020). doi: 10.3389/fchem.2020.00295
Ermakov A V, Verkhovskii R A, Babushkina I V, Trushina D B, Inozemtseva O A, Lukyanets E A, Ulyanov V J, Gorin D A, Belyakov S and Antipina M N.
In Vitro Bioeffects of Polyelectrolyte Multilayer Microcapsules Post-Loaded with Water-Soluble Cationic Photosensitizer. Pharmaceutics, 2020, 12, 7, 610. DOI 10.3390/pharmaceutics12070610;
Hamidreza Aboulkheyr Es, Bahareh Bigdeli, Sareh Zhand, Amir R. Aref, Jean P. Thiery, Majid E. Warkiani
Mesenchymal stem cellsinducePD‐L1 expression through the secretion of CCL5 in breast cancer cells. DOI: 10.1002/jcp.30135
Other laboratories and scientists
Hosting organization
Field of studies
City
Invited researcher
Time span of the project
Research Centre for Magnetic Resonance in Medicine

ITMO University

Health studies

St. Petersburg

Bendahan David

France

2021-2023

«Smart Sleep» Laboratory

Saratov State University

Health studies

Saratov

Thomas Penzel

2019-2021

Laboratory of Experimental Oncology

N. I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Health studies

Moscow

Marcus Conrad

2019-2021